# Identification of Lethal Mutations in Yeast Threonyl-tRNA Synthetase Revealing Critical Residues in Its Human Homolog*

Received for publication, August 12, 2014, and in revised form, November 3, 2014 Published, JBC Papers in Press, November 21, 2014, DOI 10.1074/jbc.M114.599886

Zhi-Rong Ruan<sup>‡</sup>, Zhi-Peng Fang<sup>‡</sup>, Qing Ye<sup>‡</sup>, Hui-Yan Lei<sup>‡</sup>, Gilbert Eriani<sup>§</sup>, Xiao-Long Zhou<sup>†‡</sup>, and En-Duo Wang<sup>¶‡</sup>

From the <sup>‡</sup>Center for RNA Research, State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yue Yang Road, Shanghai 200031, China, the <sup>¶</sup>School of Life Science and Technology, ShanghaiTech University, 320 Yue Yang Road, Shanghai 200031, China, and <sup>§</sup>Architecture et Réactivité de l'ARN, Université de Strasbourg, CNRS, Institut de Biologie Moléculaire et Cellulaire, 15 Rue René Descartes, 67084 Strasbourg, France

**Background:** Eukaryotic ThrRSs exhibit four structural domains similar to bacterial ThrRSs and evolve a eukaryote-specific N-terminal extension domain.

**Results:** Essential roles of 12 crucial residues in aminoacylation and editing reactions were revealed.

**Conclusion:** The identified critical residues affected activities of ThrRS in various manners.

**Significance:** We elucidated the synthetic and editing functions of selected residues and confirmed the functional consistency between yeast and human ThrRSs.

Aminoacyl-tRNA synthetases (aaRSs) are a group of ancient enzymes catalyzing aminoacylation and editing reactions for protein biosynthesis. Increasing evidence suggests that these critical enzymes are often associated with mammalian disorders. Therefore, complete determination of the enzymes functions is essential for informed diagnosis and treatment. Here, we show that a yeast knock-out strain for the threonyl-tRNA synthetase (ThrRS) gene is an excellent platform for such an investigation. *Saccharomyces cerevisiae* ThrRS has a unique modular structure containing four structural domains and a eukaryote-specific N-terminal extension. Using randomly mutated libraries of the ThrRS gene (*thrS*) and a genetic screen, a set of loss-of-function mutants were identified. The mutations affected the synthetic and editing activities and influenced the dimer interface. The results also highlighted the role of the N-terminal extension for enzymatic activity and protein stability. To gain insights into the pathological mechanisms induced by mutated aaRSs, we systematically introduced the loss-of-function mutations into the human cytoplasmic ThrRS gene. All mutations induced similar detrimental effects, showing that the yeast model could be used to study pathology-associated point mutations in mammalian aaRSs.

During protein biosynthesis, aminoacyl-tRNA synthetases (aaRSs)<sup>3</sup> must attach the correct amino acid to the correspond-

ing tRNA molecule (1). This process supplies the ribosome with the aminoacyl-tRNAs that are essential for protein synthesis in all cells. The aaRSs are critical in ribosomal protein translation because each canonical aaRS accurately pairs its correct amino acid to the cognate tRNA isoacceptor(s). The attachment of amino acids to tRNAs by aaRSs is performed in two steps. The amino acid is first activated with ATP to form an activated aminoacyl adenylate and then transesterified to the 3'-end of the tRNA (1). Generally, there are 20 different aaRSs in living organisms, and these enzymes can be divided into two classes (I and II) of 10 members each. The active site of class I aaRSs is based on a Rossmann fold containing two consensus sequences, HIGH and KMSKS (2), whereas that of class II aaRSs contains an antiparallel β-fold catalytic center with three motifs: motifs 1, 2, and 3 (3, 4).

Accurate aminoacylation of tRNA with its cognate amino acids by aaRSs is essential for quality control of protein synthesis, because a mischarged non-cognate amino acid may be incorporated into the nascent peptide chain after aminoacylation (1). Challenged by a large pool of proteinaceous amino acids and amino acid analogs, some aaRSs cannot discriminate accurately between cognate and non-cognate amino acids. For example, Ile is structurally similar to Leu, differing only by a branched methyl group, and can be activated by leucyl-tRNA synthetase (LeuRS, one specific aaRS is abbreviated as its three-letter amino acid code and "RS") (5). To maintain translational fidelity, several aaRSs evolved proofreading (editing) mechanisms to hydrolyze either misactivated amino acids or misacylated tRNAs, which are termed pretransfer editing or post-transfer editing, respectively (6, 7). Editing activities catalyzed by aaRSs are essential for organisms to sustain normal metabolism. Editing dysfunction causes growth defects in bacteria (8) and mitochondrial abnormality in yeast (9). In the last decade, more and more disease-causing mutations have been found in the aaRS-coding genes. For example, a collection of mutations

<footnote>* This work was supported by National Key Basic Research Foundation of China Grant 2012CB911000, Natural Science Foundation of China Grant 31130064, and Committee of Science and Technology in Shanghai Grant 12JC1409700.</footnote>

<footnote n="1">1 To whom correspondence may be addressed. Tel.: 86-21-5492-1241; Fax: 86-21-5492-1011; E-mail: xlzhou@sibcb.ac.cn.</footnote>

<footnote n="2">2 To whom correspondence may be addressed. Tel.: 86-21-5492-1241; Fax: 86-21-5492-1011; E-mail: edwang@sibcb.ac.cn.</footnote>

<footnote n="3">3 The abbreviations used are: aaRS, aminoacyl-tRNA synthetase; *EcThrRS*, *ScThrRS*, and *HsThrRS*, *E. coli*, *S. cerevisiae*, and *H. sapiens* threonyl-tRNA synthetase, respectively.</footnote>
Selected Lethal Mutations in Threonyl-tRNA Synthetase

located at the aminoacylation domain of both GlyRS and TyrRS
leads to Charcot-Marie-Tooth disease (10–12). A mutation
located in the editing domain of AlaRS causes cerebellar ataxia
(13).

Together with SerRS, AlaRS, GlyRS, ProRS, and HisRS, ThrRS belongs to the class Ila aaRSs and is a dimer (14, 15). *Escherichia coli* ThrRS (*EcThrRS*) forms the dimeric core comprising the synthetic catalytic and C-terminal tRNA anticodon binding domain. Two extra domains on the N-terminal side of each monomer protrude outside the core, forming the editing domains of the dimer, which also provide a binding interface to the minor groove of the tRNA acceptor stem (14). In contrast to other synthetases, ThrRS only activates a small number of non-cognate amino acids, such as β-hydroxynorvaline and Ser (16). A zinc ion found in the synthetic active site is implicated in Thr recognition and discrimination against non-cognate amino acids. The zinc atom imposes a strict structural geometry and controls the interacting distance with the amino acid substrate. With Thr, the side chain hydroxyl is at the ideal distance of 2.38 Å from the zinc atom. In the case of the isosteric amino acid Val, an obvious clash with one of its methyl groups would create steric hindrance alone and prevent its activation. In this way, ThrRS efficiently discriminates against amino acids possessing methyl groups but discriminates less well against amino acids with a hydroxyl group, such as Ser (17). Hydrolysis of the erroneously aminoacylated Ser occurs in the distant N2 editing domain by a mechanism of post-transfer editing ensuring faithful aminoacylation. In the editing site, two His residues (His<sup>73</sup> and His<sup>77</sup>) are responsible for hydrolyzing the misacylated Ser-tRNA<sup>Thr</sup> (17). In contrast, most archaeal ThrRSs possess a unique N-terminal editing domain unrelated to the bacterial N2 domain (18, 19) but homologous to the D-aminoacyl-tRNA deacylase that removes D-amino acids from mischarged tRNAs. Moreover, several crenarchaeal species contain two genes to encode either the catalytic (ThrRS-cat) or editing (ThrRS-ed) enzymes. ThrRS-cat performs aminoacylation, and ThrRS-ed contains an editing domain to hydrolyze mischarged Ser-tRNA<sup>Thr</sup> in trans (19, 20).

Theoretically, the molecular mass of a subunit in the dimeric ThrRS from *Saccharomyces cerevisiae* (*ScThrRS*) is 84.5 kDa, comprising 734 amino acid residues. In terms of primary sequence, eukaryotic ThrRSs, such as *ScThrRS* and *Homo sapiens* cytoplasmic ThrRS (*HsThrRS*), resemble their bacterial counterparts. However, detailed analysis revealed several different characteristics between them. First, despite retaining crucial editing amino acid residues (such as His<sup>151</sup> and His<sup>155</sup> in *ScThrRS*, counterparts of His<sup>73</sup> and His<sup>77</sup> of *EcThrRS*) in eukaryotic ThrRSs, the periphery elements in both the N1 and N2 domains of eukaryotic ThrRSs display significant differences from their bacterial counterparts. Second, the most striking difference is the fusion of a unique eukaryotic ThrRSs-specific N-terminal extension (N-extension) whose relevance in aminoacylation, editing, or protein structure is not completely understood (Fig. 1, A and B). A previous study found that a partial deletion mutant at the N-extension of *ScThrRS* (*ScThrRS-Δ40*) affected catalytic parameters; however, the possibility of a major structural effect could not be ruled out (21). Furthermore, some conserved residues exist in the N-extension-containing ThrRSs, highlighting their potential role in

protein function and/or structure. For example, an arginine residue (Arg⁵² in *ScThrRS*) is absolutely conserved in the N-extension of eukaryotic ThrRSs (Fig. 1B), suggesting its potentially critical role for eukaryotic N-extension/ThrRSs. Therefore, further detailed investigation of the effect of conserved Arg⁵² on the enzymatic properties using various *in vivo* and *in vitro* methods is required.

Although the active site of bacterial ThrRS has been studied extensively by structural and functional approaches (14, 22, 23), little research has been done on eukaryotic ThrRSs. Here, we aimed to identify the functional features of *ScThrRS* using a genetic tool that is useful for capturing important residues in the dynamic process of aminoacylation and editing (24). Instead of a rational targeting of residues on the protein, we constructed two randomly mutated *ScThrRS* libraries, a yeast *thrS* random mutagenesis library (*thrS* library) and an Arg⁵²-specific mutagenesis library (Arg⁵² library), to identify important amino acid residues for enzymatic activities and to characterize the function of Arg⁵² in the N-extension domain, respectively. The two libraries were transformed into a yeast *thrS* knock-out strain. By plasmid shuffling, we isolated and identified 12 lethal or growth-deficient mutants of *ScThrRS*. The selection procedure could map the critical residues and enzyme functions efficiently, because the 12 mutants were found in the four modules of *ScThrRS*, including the N-extension, N2, aminoacylation, and anticodon binding domains. We present a picture of the functions of several residues in the aminoacylation and editing reactions. The results also show the importance of the dimer interface for enzyme activity. Several mutants whose functional importance cannot be assessed from the structural data are selected, demonstrating the importance of this type of approach in the context of a structure-function relationship study. The essential role of the conserved Arg⁵² of the N-extension in maintaining protein structure/function is described. Finally, we show that introducing the same mutation into *HsThrRS* also leads to inactive proteins and exhibits a protein amount similar to that of the corresponding *ScThrRS* mutant, indicating functional consistency of eukaryotic ThrRSs. This opens perspectives on further studies on the human enzyme and its potential derived mutants that cause various types of human diseases.

EXPERIMENTAL PROCEDURES

*Materials*—L-Thr, L-Ser, 5'-GMP, GTP, UTP, CTP, ATP, MgCl₂, Tris-HCl (pH 7.5), dithiothreitol, isopropyl β-D-1-thiogalactopyranoside, bovine serum albumin (BSA), tetrasodium pyrophosphate, inorganic pyrophosphate, and activated charcoal were obtained from Sigma-Aldrich. [³H]Thr was from Biotrend Chemicals (Destin, FL). [¹⁴C]Ser and [α-³²P]ATP were obtained from PerkinElmer Life Sciences. The gel extraction kit, plasmid extraction kit, and yeast plasmid extraction kit were purchased from TIANGEN Biotech (Beijing, China). The dNTP mixture, KOD-Plus-Neo high fidelity DNA polymerase, and KOD-plus mutagenesis kit were purchased from TOYOBO (Osaka, Japan). 5-fluoroorotic acid (5-FOA), pyrophosphatase, T4 ligase, and restriction endonucleases were purchased from Thermo Fisher Scientific. Ni²⁺-nitrilotriacetic acid Superflow was from Qiagen (Hilden, Germany). BioSune (Shanghai,
Selected Lethal Mutations in Threonyl-tRNA Synthetase

China) synthesized the oligonucleotides. The yeast transformation kit was from Clontech. The protease inhibitor mixture was from Roche Applied Science. The mouse anti-His₆ tag (M20001), anti-GAPDH (M20028), anti-FLAG (M20008), and anti-c-Myc (M20002) antibodies were purchased from Abmart (Shanghai, China).

*Construction of Libraries and Selection of ScThrRS Mutants*—The construction of the yeast recipient strain with a disrupted *thrS* gene (*ScΔthrS*) (BY4743, *thrS*⁻, pRS426-*ScThrRS*) has been described in our laboratory (21). In this knock-out strain, the G418 resistance gene replaced the chromosomal *thrS* gene. The wild-type *thrS* gene was cloned into pRS426 (containing *URA3*) and p425TEF (containing *LEU2*) (25) to generate the rescuing plasmid pRS426-*ScThrRS* (*thrS*⁺, *Ura*⁺) and the selection plasmid p425TEF-*ScThrRS* (*thrS*⁺, *Leu*⁺), respectively. Two libraries based on the selection plasmid were constructed.

The first yeast *thrS* library was obtained by random mutagenesis of p425TEF-*ScThrRS*. Random mutagenesis can be achieved by several methods, such as error-prone PCR amplification, the use of *E. coli* mutator strain, or mutagenic agents (26, 27). We used hydroxylamine hydrochloride treatment of p425TEF-*ScThrRS*. Hydroxylamine causes C to T and G to A transitions by demutation, with a frequency of less than 0.3% (27). Briefly, p425TEF-*ScThrRS* (50 µg) was incubated in 2 ml of 0.8 M hydroxylamine hydrochloride, 50 mM sodium phosphate, 1 mM EDTA, pH 7.0, for 48 h at 37 °C. The DNA was then precipitated by ethanol at -20 °C overnight and recovered by centrifugation at 12,000 × g for 30 min. DNA sequencing of 20 *thrS* genes from this library was employed to confirm the mutagenic efficiency and the quality of this library. Twelve genes were found to have a single mutation in their ORFs; thus, the mutation efficiency of this library was about 60%.

The second Arg⁵² library was produced by PCR using oligonucleotide-directed site-specific mutagenesis to fully randomize residue Arg⁵² of *ScThrRS*. The oligonucleotide for saturating mutagenesis was 5'-NNSATTGAAATGTTTGACAGATT-3', where N represents an equimolar mixture of the four deoxynucleotides, and S represents an equimolar mixture of G and C (the reading frame of NNS decodes Arg⁵² in the native enzyme). A conventional reverse primer (5'-TTCCTCGATGAAAGTTGGTT-3') was used. PCR amplification was performed using p425TEF-*ScThrRS* as the template, following the protocol of the KOD-plus mutagenesis kit. Theoretically, such an Arg⁵² library should contain 32 variants (4 × 4 × 2) generating the 19 other amino acids, and the mutation efficiency should be nearly 100% because the p425TEF-*ScThrRS* template was digested by DpnI according to the KOD-plus mutagenesis kit. Indeed, DNA sequencing of 10 *thrS* genes from the Arg⁵² library confirmed the mutagenesis efficiency; nine genes were found to contain a single mutation at position 52, suggesting that mutagenic efficiency was around 90%.

The *thrS* and Arg⁵² libraries were introduced separately into the yeast strain *ScΔthrS*, according to the Clontech yeast transformation manual, and transformants were selected on SD/Leu⁻/Ura⁻ plates. Drop tests were subsequently performed on SD/Leu⁻/Ura⁻ and SD/Leu⁻/5-FOA plates. After incubation for 48–96 h, clones that grew very slowly or could

not grow on the SD/Leu⁻/5-FOA plate (5-FOA⁸) and thus could not lose the rescuing *thrS*⁺ plasmid were chosen as candidates harboring inactive ThrRS genes. Mutated p425TEF-*ScThrRS* plasmids were recovered from the colonies that appeared on original SD/Leu⁻/Ura⁻ plates, and the *thrS* genes were sequenced.

Subsequently, control wild-type *thrS* and mutated *thrS* genes were cloned into a modified p425TEF(His) vector, which allows expression of the mutated *thrS* genes with a C-terminal His tag, facilitating subsequent quantification of the protein amount. The resulting constructs were introduced into *ScΔthrS* to confirm the phenotypes, eliminating any side effects of mutations occurring at other sites in the selection plasmid.

*Preparation of Yeast Cell Lysates and Western Blot Assay*—Clones sensitive to 5-FOA were grown on SD/Leu⁻/Ura⁻ liquid medium. The yeast expressed the genes from both the rescue-plasmid (pRS426-*ScThrRS* (without His₆ tag)) and the selection plasmid (p425TEF(His)-*ScThrRS* mutant (with His₆ tag)). Western blot was performed with an antibody directed against the His₆ tag to detect the amount of *ScThrRS* and its variants *in vivo*. Yeast cells were harvested by centrifugation at 3000 × g for 5 min at 4 °C. Cells were resuspended in ice-cold lysis buffer containing 50 mM sodium phosphate (pH 8.0), 300 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10% glycerol and lysed in a glass bead grinder at 4 °C for 20 min (28).

Proteins were separated by 10% SDS-PAGE gel electrophoresis and transferred to PVDF membranes. The membranes were blocked in PBS plus 0.05% Tween 20 buffer containing 5% nonfat dry milk. Membranes were separately immunoblotted with either anti-His₆ antibody or anti-GAPDH antibody. After incubation with the horseradish peroxidase-conjugated secondary antibody, the light emission was monitored using LAS4000 (FUJIFILM) and the SuperSignal West Pico Trial Kit (Thermo Fisher Scientific). Results were quantified using Multi Gauge version 3.0 software (FUJIFILM), and the amounts of *ScThrRS* or variants were normalized to the GAPDH amount. The amount of wild-type *ScThrRS* from the selection plasmid was designed as 100%.

*Cloning and Expression of ScThrRS Gene and tRNA<sup>Thr</sup> Transcription*—pET22b-*ScThrRS* was constructed to obtain C-terminal His₆-tagged ThrRS in *E. coli* in our laboratory (21). Here, the mutated *thrS* genes (including point and deletion mutations) were constructed using the KOD-plus mutagenesis kit, and mutants were identified by DNA sequencing. Gene expression and protein purification of *ScThrRS* and its mutants were performed as previously reported (21). Transcripts of *SctRNA<sup>Thr</sup>* (AGU, CGU, and UGU) were obtained by *in vitro* T7 RNA polymerase run-off transcription, as described previously (21).

*Measurements of Kinetic Parameters, Deacylation, and AMP Formation*—*K*<sub>m</sub> and *k*<sub>cat</sub> values of *ScThrRS* for amino acid in the Thr activation reaction and for tRNA<sup>Thr</sup> isoacceptors (including AGU, CGU, and UGU) in the aminoacylation reaction were determined as described previously (21).

Misaminoacylated Ser-tRNA<sup>Thr</sup>(AGU) (Ser-tRNA<sup>Thr</sup>) was obtained via mischarging with Ser by *ScThrRS*-H151A/H155A (21). The deacylation activities of *ScThrRS* variants for mis-
Selected Lethal Mutations in Threonyl-tRNA Synthetase

charged [¹⁴C]Ser-tRNA<sup>Thr</sup> were measured as reported previ-
ously (21). Editing activities were also determined by measuring
the AMP formation in the presence of the non-cognate Ser.
AMP formation was monitored by thin-layer chromatography
(TLC) plates according to previous studies (29, 30) with adjust-
ment for conditions for ScThrRS (21).

Measurement of Equilibrium Dissociation Constants (k_d) for tRNA by Filter Binding Assays—The nitrocellulose filter binding method was used to monitor ScThrRS-[³²P]tRNA<sup>Thr</sup> complex formation (31). Nitrocellulose membranes (0.22 µm) were presoaked in washing buffer (50 mM potassium phosphate (pH 5.5), 50 mM MgCl₂). Binding assays were performed at 4 °C for 30 min in a 50-µl reaction mixture containing 60 mM Tris-HCl (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 56 nM SctRNA<sup>Thr</sup>(AGU) (20,000 cpm, containing 1 nM [³²P]SctRNA<sup>Thr</sup>(AGU)), and various concentrations of ScThrRSs (1–20 µM). The samples were then applied and filtered through the nitrocellulose membrane. The filters were washed with 0.3 ml of washing buffer and dried, and the radioactivity was counted. Data analysis using GraphPad PRISM software produced the k_d values.

Cell Culture, Transfection, and Co-immunoprecipitation—
The genes of wild-type *ScThrRS*, and its mutants *ScThrRS-G356N* and *-P627L* were amplified from their pET22b constructs and then cloned into eukaryotic expression vectors pCMV-3Tag-3A (with a C-terminal 3×FLAG tag) and pCMV-3Tag-4A (with a C-terminal 3×C-Myc tag).

Plasmid pCMV-3Tag-4A-*ScThrRS*, together with either pCMV-3Tag-3A-*ScThrRS* or pCMV-3Tag-3A, was co-transfected in HEK293T cells using Lipofectamine 2000 to express the genes of FLAG- or c-Myc-*ScThrRS*, according to a method described previously (32). The same method was used to express the genes of *ScThrRS-G356N* and *-P627L*. After transfection for 36 h, cells were washed three times with ice-cold PBS and lysed with lysis buffer (20 mM HEPES (pH 7.5), 100 mM NaCl, 0.2 mM EDTA, 10% glycerol, 1% Nonidet P-40, 1 mM KF, 0.02 mg/ml protease inhibitor mixture). Cell lysates were centrifuged at 12,000 × g for 15 min at 4 °C. To immunoprecipitate *ScThrRS* and its variants, the cell lysates were incubated overnight at 4 °C with anti-FLAG antibodies and then conjugated to agarose beads according to the Protein A/G-agarose manual (Abmart). Samples of whole cell lysates and immune complexes were separated by 10% SDS-PAGE and detected by Western blot using anti-FLAG or anti-c-Myc antibody.

Complementation Assays by *HsThrRS* Mutants—Wild-type *HsThrRS* was cloned into p425TEF(His). Mutations corresponding to selected mutants in *ScThrRS* were introduced into the *HsThrRS* gene by site-directed mutagenesis. The genes of mutated *HsThrRSs* were introduced into *ScΔthrS* and selected on *SD/Leu*⁻/Ura*⁻* plates. A single colony of each transformant was grown in liquid *SD/Leu*⁻/Ura*⁻* medium. To perform comparative drop tests, yeast cultures were diluted to 1 *A*<sub>600</sub>, and the same volume was dropped on *SD/Leu*⁻/5-FOA plates. The level of growth and complementation was roughly quantified after comparison with that of *ScΔthrS* strains containing *HsThrRS* variants or *ScThrRS*. The amounts of wild-type *HsThrRS* and variants in *ScΔthrS* were checked by Western blot using the anti-His<sub>6</sub> antibody as described above.

RESULTS

Selection and Identification of 11 Growth-deficient or Lethal Mutations in Yeast thrS Library—Random mutagenesis coupled with *in vivo* selection was used to screen the expression of all *thrS* genes to identify crucial positions in *ScThrRS* involved in synthetic or editing catalysis, substrate binding, folding, and stability. Hydroxylamine mutagenesis was used to produce a *thrS* library harboring single or few mutations. The library was screened in the yeast *thrS* knock-out strain *ScΔthrS* for the ability of the mutated genes to replace the rescuing plasmid harboring a *URA3* gene. 5000 colonies from the library were screened, and 31 clones were shown to be 5-FOA-sensitive and unable to lose the rescuing *thrS*⁺, *Ura*⁺ plasmid. The full-length *ScThrRS* gene of the 31 mutants was sequenced. All 31 mutations were found to be G→A or C→T transitions, which is consistent with the deamination properties of hydroxylamine (26). Among them, 20 of the selected genes carried nonsense mutations at variable positions. In addition, two lethal clones simultaneously harbored two mutations in their ORFs (M70K/ Q629stop and W150stop/S201F). To determine which mutation was responsible for the lethal phenotype, we isolated the two missense mutations and two nonsense mutations by mutagenesis and tested them in *ScΔthrS* strain. The assay confirmed that mutations W150stop and Q629stop were lethal, whereas M70K and S201F were viable (data not shown). Thus, two nonsense mutations (W150stop and Q629stop) were responsible for the lethality of the two lethal clones. However, too many residues were truncated in these two nonsense mutations, with 585 and 106 residues, respectively, in W150stop and Q629stop. Therefore, no further investigation was performed on *ScThrRS-W150stop* or *-Q629stop* mutant. Interestingly, two lethal nonsense mutations (Q704stop and Q719stop) introduced stop codons that were only 31 and 16 residues from the C terminus, suggesting an important function of the C-terminal domain of the enzyme. The remaining 11 mutations were missense mutations. Two of them (G145D and P627L) were identified twice, and the other seven (S308F, G356N, S457F, G458D, R461H, G604E, and G685D) were found only once.

Therefore, 11 different mutants with growth-deficient or lethal phenotypes, including *ScThrRS-G145D*, *-S308F*, *-G356N*, *-S457F*, *-G458D*, *-R461H*, *-G604E*, *-P627L*, *-G685D*, *-Q704stop*, and *-Q719stop*, were found in the *thrS* library (Fig. 1A and Table 1). The 11 mutated *thrS* genes were cloned into vector p425TEF(His), and the constructs were re-introduced into *ScΔthrS* strain to confirm the lethal or growth-impaired phenotypes on *SD/Leu*⁻/5-FOA medium. The yeast *ScΔthrS* containing *ScThrRS-G145D* and *-S457F* was growth-deficient; the other mutations were lethal (Fig. 2A). Western blot showed that the genes of all mutants could express in yeast (Fig. 2B). Therefore, the inability of those mutants to support yeast growth was probably due to their reduced amount and/or their decreased enzymatic activities and not to an incapacity for mutated gene expression. The amounts of the mutant proteins were different, from 5% (G145D) to about 80% (S457F, G458D, and G685D) of the amount of the wild-type *ScThrRS* (Fig. 2C), which was probably caused by protein instability and/or degradation.
Selected Lethal Mutations in Threonyl-tRNA Synthetase

<figure><img src="image_1.png" /><figcaption>FIGURE 1. Domain and sequence analysis of the selected residues of ScThrRS. A, schematic representation of the domain composition of ScThrRS, based on the structural modules of EcThrRS. 12 selected ScThrRS mutations were found in four domains of ScThrRS. Eight mutated residues were conserved in ScThrRS and HsThrRS, which are shown with dotted lines. B, sequence alignment of N-terminal peptidic extensions of various eukaryotic ThrRSs, showing the strict conservation of an arginine residue (highlighted by a box) at position 52 in ScThrRS. C, multiple sequence analysis of several peptides containing the selected residues, which are highlighted by arrows; other parts of various ThrRSs are omitted for clarity. Ca, Candida albicans; Ce, Caenorhabditis elegans; Cf, Canis familiaris; Dm, Drosophila melanogaster; Dr, Danio rerio; Gl, Giardia lamblia; Hs, Homo sapiens; Lb, Leishmania braziliensis; Lm, Leishmania major; Mm, Mus musculus; Sc, S. cerevisiae; Tb, Trypanosoma brucei; T. co, Trypanosoma congolense; T. cr, Trypanosoma cruzi; Tv, Trypanosoma vivax.</figcaption></figure>

<table><caption>TABLE 1
Selected ScThrRS mutations, their growth phenotypes, corresponding residues in EcThrRS, and location in the protein domains</caption><thead><tr><th>ScThrRS mutations</th><th>Growth phenotype</th><th>Corresponding EcThrRS residues</th><th>Protein domain</th></tr></thead><tbody><tr><td>R52F</td><td>Lethal</td><td>No equivalent<sup>a</sup></td><td rowspan="2">N-extension</td></tr><tr><td>M70K</td><td>Normal</td><td>Not analyzed<sup>b</sup></td></tr><tr><td>G145D</td><td>Deficient</td><td>Gly<sup>67</sup></td><td rowspan="3">N2 (editing)</td></tr><tr><td>S201F</td><td>Normal</td><td>Not analyzed<sup>b</sup></td></tr><tr><td>S308F</td><td>Lethal</td><td>Ala<sup>222</sup></td></tr><tr><td>G356N</td><td>Lethal</td><td>Gly<sup>270</sup></td><td rowspan="5">Aminoacylation</td></tr><tr><td>S457F</td><td>Deficient</td><td>His<sup>371</sup></td></tr><tr><td>G458D</td><td>Lethal</td><td>Gly<sup>372</sup></td></tr><tr><td>R461H</td><td>Lethal</td><td>Arg<sup>375</sup></td></tr><tr><td>G604E</td><td>Lethal</td><td>Gly<sup>316</sup></td></tr><tr><td>P627L</td><td>Lethal</td><td>Pro<sup>539</sup></td><td rowspan="4">Anticodon binding</td></tr><tr><td>G685D</td><td>Lethal</td><td>Gly<sup>597</sup></td></tr><tr><td>Q704Stop</td><td>Lethal</td><td>Asp<sup>615</sup></td></tr><tr><td>Q719Stop</td><td>Lethal</td><td>Gln<sup>630</sup></td></tr></tbody></table>

According to the crystallographic structure of the EcThrRS-tRNA<sup>Thr</sup> complex (14), the mutations in the enzyme were localized. The mutations were clustered in the three main functional domains of ScThrRS. Two mutations, G145D and S308F, were located in the editing domain; six mutations (G356N, S457F, G458D, R461H, G604E, and P627L) were clustered in the aminoacylation active site; and three mutations (G685D, Q704stop, and Q719stop) were co-localized in the tRNA anticodon binding domain (Figs. 1A and 2D).

Mutations in the N2 Domain Decrease the Editing Activity—G145D and S308F were located in the second half of the editing domain (N2 domain). G145D induced a severe growth defect compared with native enzyme, whereas S308F induced complete lethality. When comparing the ThrRS sequences, it appeared that Gly<sup>145</sup> is only a semiconserved residue and is

often an Ala residue in other eukaryotic ThrRSs. On the other hand, Ser<sup>308</sup> is a highly conserved residue (Fig. 1C). To explore the effect of the mutations on the catalytic properties of the enzyme, the genes of two mutated His-tagged proteins were overexpressed in E. coli, and the mutations were purified by Ni<sup>2+</sup> affinity chromatography. The Thr activation parameters of ScThrRS-G145D and -S308F showed unmodified K<sub>m</sub> and a slight decrease in k<sub>cat</sub> (2.6 ± 0.2 and 2.4 ± 0.2 s<sup>-1</sup>, respectively) compared with that of the wild-type k<sub>cat</sub> (3.2 ± 0.1 s<sup>-1</sup>; Table 2). In the tRNA<sup>Thr</sup>-charging reaction, the k<sub>cat</sub> values of both mutants were significantly decreased, retaining only 11 and 5% of the value for the native enzyme. However, the k<sub>d</sub> and K<sub>m</sub> values of the two mutants for tRNA<sup>Thr</sup> were slightly increased. Their catalytic efficiencies (k<sub>cat</sub>/K<sub>m</sub>) were 11.4- and 32.5-fold lower, respectively, than the wild type (Tables 3 and 4). These results showed that both mutations had little effect on Thr activation and the affinity for tRNA<sup>Thr</sup> but obviously decreased the rate of tRNA aminoacylation, despite their presence in the N2 editing domain. Notably, the mutations are located at the interface between the editing and aminoacylation domains (Fig. 2D), suggesting a distal effect on the synthetic active site. The mutations may disturb the subtle structure of the active site and thus affect the rate of aminoacylation. Moreover, Western blot showed that *in vivo*, the amounts of ScThrRS-G145D and -S308F were significantly decreased compared with that of native enzyme (Fig. 2, B and C). Taken together, the results suggested that the deleterious effect of the mutations might act both at the catalytic level and on the enzyme concentration in the cell.

Gly<sup>145</sup> and Ser<sup>308</sup> are located in the N2 domain; therefore, the editing activities of ScThrRS-G145D and -S308F were monitored. In the absence of tRNA<sup>Thr</sup> and in the presence of Ser as the non-cognate amino acid, the k<sub>obs</sub> of ScThrRS-G145D in

<footnote><sup>a</sup> Arg<sup>52</sup> is located in the eukaryote-specific N-extension domain and thus has no equivalent in EcThrRS.</footnote>

<footnote><sup>b</sup> M70K and S201F were not studied (see "Results").</footnote>
Selected Lethal Mutations in Threonyl-tRNA Synthetase

<figure><img src="image_2.png" /><figcaption>FIGURE 2. Twelve mutants exhibited lethal or growth-deficient phenotypes. A, *ScThrRS*-R52F, -G145D, -S308F, -G349N, -S457F, -G458D, -R461H, -G604E, -P627L, -G685D, -Q704stop, and -Q719stop were cloned into p425TEF(His) and introduced in strain *ScΔthrS*, where the growth phenotypes were confirmed. Wild-type *ScThrRS* and empty p425TEF(His) were used as positive and negative controls, respectively. Drop tests were performed on SD/Leu⁻/5-FOA plate with an equal number of cells. B, Western blot (WB) showing the amounts of different *ScThrRS* mutants. GAPDH was used as a control. C, quantification of the Western blot. The amounts of *ScThrRS* mutants were normalized according to the endogenous GAPDH. The amount of wild-type *ScThrRS* was designed as 100%. Relative protein amounts were calculated based on at least two independent Western blot assays and shown in parentheses with S.D. values omitted for clarity. D, corresponding residues (shown as red spheres) are shown on the crystallographic structure of *EcThrRS*-tRNA**Thr** complex (Protein Data Bank code 1QF6). The protein modules are colored green (editing domain), cyan (catalytic domain), and orange (anticodon binding domain). tRNA**Thr** is shown in pink. Error bars, S.D.</figcaption></figure>

AMP formation was (3.1 ± 0.2) × 10⁻³ s⁻¹, which was similar to the (2.8 ± 0.8) × 10⁻³ s⁻¹ of the native enzyme. For *ScThrRS*-S308F, the *k*<sub>obs</sub> for AMP formation was significantly decreased to (0.5 ± 0.1) × 10⁻³ s⁻¹ (Table 5 and Fig. 3A). Therefore, S308F might be the first identified mutation of eukaryotic ThrRSs to affect tRNA-independent pretransfer editing. In the presence of tRNA<sup>Thr</sup>, which measured the total editing reaction, the *k*<sub>obs</sub> values of *ScThrRS*-G145D and -S308F in AMP formation reaction were (4.1 ± 0.4) × 10⁻³ s⁻¹ and (2.9 ± 0.4) × 10⁻³ s⁻¹, respectively, representing only 27.5 and 19.4% of the wild-type activity (Table 5 and Fig. 3A). Moreover, a deacylation assay of preformed mischarged Ser-tRNA<sup>Thr</sup> was performed. The deacylation curves showed that both mutants were unable to hydrolyze mischarged Ser-tRNA<sup>Thr</sup> (Fig. 3B).

Thus, the results showed that the G145D mutation impacted the tRNA-dependent editing activity but not the tRNA-independent editing. However, both the tRNA-independent and -dependent editing activities of the *ScThrRS*-S308F were impaired. Although the two residues are not located in the previously identified editing pocket (17), their mutations have a profound effect on the editing activity of eukaryotic ThrRS.

Mutations G356N and P627L Impair Dimer Formation—
Amino acid activation and tRNA aminoacylation assays
showed that *ScThrRS*-G356N and -P627L had completely lost
their synthetic activity (Table 2 and 3). Moreover, the *k*<sub>d</sub> values
for tRNA mostly increased (Table 4). However, the crystal
structure of *EcThrRS* showed that Gly<sup>270</sup> and Pro<sup>539</sup> of
*EcThrRS*, the corresponding residues of Gly<sup>356</sup> and Pro<sup>627</sup> in
# Selected Lethal Mutations in Threonyl-tRNA Synthetase

<caption>**TABLE 2**</caption>

<table><caption>Kinetic parameters of ScThrRS and its variants for Thr in amino acid activation reaction</caption><thead><tr><th>Enzyme</th><th>k<sub>cat</sub><sup>a</sup></th><th>K<sub>m</sub><sup>a</sup></th><th>k<sub>cat</sub>/K<sub>m</sub><sup>m</sup></th><th>Relative k<sub>cat</sub>/K<sub>m</sub></th><th>Loss of catalytic efficiency</th></tr><tr><td></td><td>s<sup>-1</sup></td><td>m<sub>M</sub></td><td>m<sub>M</sub><sup>-1</sup> s<sup>-1</sup></td><td>%</td><td>-fold</td></tr></thead><tbody><tr><td>WT</td><td>3.2 ± 0.1</td><td>0.22 ± 0.02</td><td>14.6</td><td>100</td><td></td></tr><tr><td>R52F</td><td>1.3 ± 0.1</td><td>0.23 ± 0.02</td><td>5.7</td><td>39.1</td><td>2.6</td></tr><tr><td>R52A</td><td>1.8 ± 0.1</td><td>0.24 ± 0.04</td><td>7.5</td><td>51.7</td><td>1.9</td></tr><tr><td>R52D</td><td>1.6 ± 0.2</td><td>0.26 ± 0.05</td><td>6.1</td><td>42.0</td><td>2.4</td></tr><tr><td>R52K</td><td>3.3 ± 0.1</td><td>0.21 ± 0.01</td><td>15.5</td><td>106.4</td><td></td></tr><tr><td>G145D</td><td>2.6 ± 0.2</td><td>0.22 ± 0.05</td><td>12.0</td><td>81.9</td><td>1.2</td></tr><tr><td>S308F</td><td>2.4 ± 0.2</td><td>0.24 ± 0.03</td><td>9.9</td><td>67.7</td><td>1.5</td></tr><tr><td>G356N</td><td>NM<sup>b</sup></td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>S457F</td><td>3.4 ± 0.2</td><td>0.33 ± 0.02</td><td>10.4</td><td>71.0</td><td>1.4</td></tr><tr><td>G458D</td><td>1.0 ± 0.1</td><td>2.1 ± 0.3</td><td>0.5</td><td>3.4</td><td>29.2</td></tr><tr><td>R461H</td><td>1.4 ± 0.1</td><td>2.9 ± 0.1</td><td>0.5</td><td>3.4</td><td>29.8</td></tr><tr><td>G604E</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>P627L</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>G685D</td><td>4.1 ± 0.3</td><td>0.25 ± 0.02</td><td>16.4</td><td>112.4</td><td></td></tr><tr><td>C-Δ3</td><td>3.4 ± 0.3</td><td>0.35 ± 0.03</td><td>9.7</td><td>66.6</td><td>1.5</td></tr><tr><td>C-Δ5</td><td>2.8 ± 0.3</td><td>0.38 ± 0.09</td><td>7.4</td><td>50.7</td><td>2.0</td></tr><tr><td>C-Δ10</td><td>3.1 ± 0.2</td><td>0.43 ± 0.14</td><td>7.1</td><td>48.6</td><td>2.1</td></tr></tbody></table>

<caption>**TABLE 3**</caption>

<table><caption>Kinetic parameters of ScThrRS and its variants for tRNA<sup>Thr</sup> (AGU) in aminoacylation reaction</caption><thead><tr><th>Enzyme</th><th>k<sub>cat</sub><sup>a</sup></th><th>K<sub>m</sub><sup>a</sup></th><th>k<sub>cat</sub>/K<sub>m</sub><sup>m</sup></th><th>Relative k<sub>cat</sub>/K<sub>m</sub></th><th>Loss of catalytic efficiency</th></tr><tr><td></td><td>×10<sup>-2</sup> s<sup>-1</sup></td><td>m<sup>M</sup></td><td>m<sub>M</sub><sup>-1</sup> s<sup>-1</sup></td><td>%</td><td>-fold</td></tr></thead><tbody><tr><td>WT</td><td>2.8 ± 0.1</td><td>1.1 ± 0.1</td><td>24.7</td><td>100</td><td></td></tr><tr><td>R52F</td><td>NM<sup>b</sup></td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>R52A</td><td>0.2 ± 0.1</td><td>2.0 ± 0.3</td><td>1.0</td><td>4.3</td><td>23.1</td></tr><tr><td>R52D</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>R52K</td><td>1.7 ± 0.1</td><td>1.2 ± 0.2</td><td>13.6</td><td>54.8</td><td>1.8</td></tr><tr><td>G145D</td><td>0.30 ± 0.02</td><td>1.4 ± 0.2</td><td>2.2</td><td>8.7</td><td>11.4</td></tr><tr><td>S308F</td><td>0.14 ± 0.01</td><td>1.8 ± 0.1</td><td>0.8</td><td>3.1</td><td>32.5</td></tr><tr><td>G356N</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>S457F</td><td>0.15 ± 0.06</td><td>1.2 ± 0.1</td><td>1.2</td><td>5.0</td><td>20.0</td></tr><tr><td>G458D</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>R461H</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>G604E</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>P627L</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>G685D</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td><td>NM</td></tr><tr><td>C-Δ3</td><td>1.5 ± 0.2</td><td>1.4 ± 0.1</td><td>10.4</td><td>42.1</td><td>2.4</td></tr><tr><td>C-Δ5</td><td>1.2 ± 0.2</td><td>1.3 ± 0.2</td><td>5.6</td><td>37.3</td><td>4.4</td></tr><tr><td>C-Δ10</td><td>1.0 ± 0.1</td><td>1.5 ± 0.2</td><td>5.1</td><td>26.2</td><td>4.9</td></tr></tbody></table>

<caption>**TABLE 4**</caption>

<table><caption>$k_d$ of ScThrRS for $SctRNA^{Thr}$ (AGU) in filter binding reaction at 4 °C</caption><thead><tr><th>Enzyme</th><th>kd<sup>a</sup></th><th>μ<sup>M</sup></th></tr></thead><tbody><tr><td>WT</td><td></td><td>3.3 ± 0.3</td></tr><tr><td>R52F</td><td></td><td>3.0 ± 0.2</td></tr><tr><td>R52D</td><td></td><td>3.1 ± 0.5</td></tr><tr><td>G145D</td><td></td><td>3.0 ± 0.8</td></tr><tr><td>G356N</td><td></td><td>13 ± 3</td></tr><tr><td>S308F</td><td></td><td>3.0 ± 0.3</td></tr><tr><td>S457F</td><td></td><td>3.8 ± 0.5</td></tr><tr><td>G458D</td><td></td><td>3.1 ± 0.5</td></tr><tr><td>R461H</td><td></td><td>3.2 ± 0.5</td></tr><tr><td>P627L</td><td></td><td>19 ± 5</td></tr><tr><td>G685D</td><td></td><td>3.9 ± 0.9</td></tr></tbody></table>

ScThrRS, are located far from the catalytic center (Fig. 4A) (14). In the case of *EcThrRS*, Gly<sup>270</sup> is located in a α-helix at the interface of the subunits of the *EcThrRS* dimer, just before specific motif 1 of class II aaRSs (14). Hydrogen bonds, salt bonds, and hydrophobic interactions connect the α-helix of one subunit and a peptide loop of another subunit (Fig. 4B). For

<caption>**TABLE 5**</caption>

<table><caption>$k_{obs}$ of AMP formation of ScThrRS and derivatives in the presence of Ser</caption><thead><tr><th>Enzyme</th><th>tRNA</th><th>k<sub>obs</sub><sup>a</sup></th><th>Relative k<sub>obs</sub></th></tr></thead><tbody><tr><td>WT</td><td>—</td><td>×10<sup>-3</sup> s<sup>-1</sup></td><td>18.9</td></tr><tr><td>WT</td><td>+</td><td>2.8 ± 0.8</td><td>18.9</td></tr><tr><td>R52F</td><td>—</td><td>14.9 ± 0.8</td><td>100</td></tr><tr><td>R52F</td><td>+</td><td>0.3 ± 0.1</td><td>2.1</td></tr><tr><td>R52D</td><td>—</td><td>0.6 ± 0.2</td><td>4.0</td></tr><tr><td>R52D</td><td>+</td><td>3.1 ± 0.2</td><td>20.6</td></tr><tr><td>G145D</td><td>—</td><td>4.1 ± 0.4</td><td>27.5</td></tr><tr><td>G145D</td><td>+</td><td>0.5 ± 0.1</td><td>3.4</td></tr><tr><td>S308F</td><td>—</td><td>2.9 ± 0.4</td><td>19.4</td></tr><tr><td>S308F</td><td>+</td><td>1.4 ± 0.1</td><td>9.3</td></tr><tr><td>C-Δ3</td><td>—</td><td>13.4 ± 0.9</td><td>89.9</td></tr><tr><td>C-Δ5</td><td>—</td><td>1.1 ± 0.2</td><td>7.1</td></tr><tr><td>C-Δ5</td><td>+</td><td>8.2 ± 0.4</td><td>54.9</td></tr><tr><td>C-Δ10</td><td>—</td><td>0.9 ± 0.2</td><td>6.2</td></tr><tr><td>C-Δ10</td><td>+</td><td>7.7 ± 0.5</td><td>51.7</td></tr></tbody></table>

<figure><img src="image_3.png" /><figcaption>FIGURE 3. Editing properties of mutants ScThrRS-G145D and -S308F. A, quantification of AMP formation in the presence of Ser and absence of tRNA by ScThrRS-WT (○), -G145D (□), and -S308F (△) or in the presence of tRNA by ScThrRS-WT (○), -G145D (□), and -S308F (△). B, deacylation assay of mischarged Ser-tRNA<sup>Thr</sup> by ScThrRS-G145D (□), -S308F (△), and -WT (○). Spon- taneous deacylation of Ser-tRNA<sup>Thr</sup> (○) was included as a control. Error bars, S.D.</figcaption></figure>

instance, residue Trp<sup>271</sup> (adjacent of Gly<sup>270</sup>) is located at only 2.71 Å from Glu<sup>292</sup> of another subunit (Fig. 4C). Therefore, the flexible residue Gly at position 270 might control the conformation of the interface, and the introduction of a bulky and more rigid Asn residue at this site probably caused a local structural rearrangement and influenced the dense network of interactions of the interface.

The second mutated residue, Pro<sup>627</sup> in ScThrRS, the equivalent of Pro<sup>539</sup> in *EcThrRS*, is located in the linker loop connecting the aminoacylation and anticodon binding domains (Figs. 2D and 4A) (14). When a Leu residue replaced the rigid Pro in the P627L mutant, the loop was probably able to become more flexible and adopt a different conformation, which influenced the dimer interface.

Therefore, we assumed that mutations G356N and P627L might be damaging for dimerization of ScThrRS. This could also explain the low amount of protein found in yeast cells, because the isolated subunits might be unstable and subjected to degradation (Fig. 2B). To test this assumption, the genes of FLAG- and c-Myc-tagged wild-type ScThrRS or ScThrRS-G356N or -P627L were co-expressed in HEK293T cells. Cell lysates were immunoprecipitated with anti-FLAG antibodies. Western blot showed that c-Myc-tagged wild-type ScThrRS could be readily co-immunoprecipitated by the anti-FLAG antibody (Fig. 4D), suggesting that c-Myc-ScThrRS and FLAG-ScThrRS subunits could form “heterodimers,” as expected. In sharp contrast, neither c-Myc-tagged ScThrRS-G356N nor

<footnote><sup>a</sup> The results are shown as the average of three independent trials ± S.D.</footnote>

<footnote><sup>b</sup> NM, activity too low to be measured.</footnote>

<footnote><sup>a</sup> The results are shown as the average of three independent trials ± S.D.</footnote>

<footnote><sup>b</sup> NM, activity too low to be measured.</footnote>

<footnote><sup>a</sup> The results are shown as the average of three independent trials ± S.D.</footnote>

<footnote><sup>a</sup> The results are shown as the average of three independent trials ± S.D.</footnote>
Selected Lethal Mutations in Threonyl-tRNA Synthetase

<figure><img src="image_4.png" /></figure>

FIGURE 4. **Impact of mutations G356N and P627L on the dimerization of ScThrRS.** A, view of the location of G356N and P627L in the two subunits (colored cyan and green) of the EcThrRS dimer (Protein Data Bank code 1QF6). The mutated residues are colored red. B, hydrogen bonds, salt bonds, and hydrophobic interactions are found at the interface of the two subunits (colored cyan and green, respectively) of EcThrRS dimer. The mutated residue Gly<sup>270</sup> (corresponding to Gly<sup>356</sup> in ScThrRS) is colored red. C, Trp<sup>271</sup> is within bonding distance of Glu<sup>292</sup> of the other subunit. D, HEK293T cells were co-transfected with pCMV-3Tag-4A-ScThrRS (c-Myc-tagged ScThrRS) in the presence of pCMV-3Tag-3A-ScThrRS (FLAG-tagged ScThrRS) or control vector pCMV-3Tag-3A. The same procedures were performed for mutants ScThrRS-G356N and -P627L. Cell lysates were immunoprecipitated with anti-FLAG antibodies conjugated to agarose beads. Western blot (WB) was carried out to detect whether c-Myc-tagged proteins were co-immunoprecipitated (IP) with FLAG-tagged proteins. Error bars, S.D.

-P627L could be co-immunoprecipitated by the anti-FLAG antibody, despite the fact that both FLAG-tagged *ScThrRS*-G356N and -P627L were well immunoprecipitated by the anti-FLAG antibodies (Fig. 4D). Thus, FLAG/c-Myc-tagged *ScThrRS*-G356N and -P627L were unable to form “heterodimers.” These results suggested that the failure to dimerize might be the cause of the lethal phenotype observed with the two mutants. *In vivo*, the single subunits are probably subjected to a rapid degradation, as observed by the low content of mutated *ScThrRS* found in the yeast cells (Fig. 2, B and C).

**Lethal Mutations in the Synthetic Active Site Domain**—One lethal mutation (G604E) was found in the class II-defining synthetase motif 3. In class II synthetases, Gly residues and other small residues are often found in the β-strand preceding the invariant Arg residue (Arg<sup>618</sup> of *ScThrRS*) (24). These small residues form the ATP-binding cavity and replacement of a Gly in a class II synthetase by a charged residue affected the enzyme activity to alter the enzyme conformation (24). In the case of *EcThrRS*, the equivalent residue Gly<sup>516</sup> (Gly<sup>604</sup> of *ScThrRS*) is only at 3.01 Å from the AMP moiety of activated Thr-AMP (Fig. 5, A and B). Furthermore, its adjacent residue, Ser<sup>517</sup>, directly contacts the AMP moiety by hydrogen bonding (14, 33). Therefore, the introduction of a negatively charged Glu residue might create a spatial hindrance with the base moiety of AMP with consequences for Thr-AMP formation. Indeed, amino acid activation kinetics showed that *ScThrRS*-G604E was completely

<figure><img src="image_5.png" /></figure>

FIGURE 5. Representations of several key residues analyzed in the present study and the network of interactions with AMP and tRNA in the catalytic center of EcThrRS. A, location of mutated residues in the catalytic center in the *EcThrRS* structure (Protein Data Bank code 1QF6). Motif 2 β-sheets, motif 2 loop, motif 3 β-sheet, and tRNA are colored orange, green, pink, and cyan, respectively. Residues His<sup>371</sup>, Gly<sup>372</sup>, Arg<sup>375</sup>, and Gly<sup>516</sup> (corresponding to Ser<sup>457</sup>, Gly<sup>458</sup>, Arg<sup>461</sup>, and Gly<sup>604</sup> of *ScThrRS*) are colored red. B, schematic representation showing the distance from Gly<sup>516</sup> or Gly<sup>372</sup> to the 2'-hydroxyl group of the AMP substrate. C, schematic representation showing the distance between His<sup>371</sup> and G70 of the tRNA. D, schematic representation showing the distance between Gly<sup>597</sup> (corresponding to Gly<sup>685</sup> of *ScThrRS*) and G35 of the tRNA.

Thr activation and tRNA<sup>Thr</sup> charging (Tables 2 and 3). Western blot also showed that the lethal effect observed in the yeast was not the consequence of protein insta-
Selected Lethal Mutations in Threonyl-tRNA Synthetase

bility because the mutation had little impact on the protein quantity (Fig. 2C).

Interestingly, three mutations (S457F, G458D, and R461H) were clustered in the motif 2 loop. The motif 2 loop (residues 449–463 in *ScThrRS*) is part of signature motif 2, connecting two antiparallel β-strands. In class II synthetases (34–36), this loop plays a critical role during catalysis by participating in the binding of amino acid, ATP, and the acceptor end of the tRNA.

Gly<sup>372</sup> in *EcThrRS* (corresponding to Gly<sup>458</sup> in *ScThrRS*) is far from AMP and does not contact the substrates (Fig. 5B) (14). However, here we showed that the lethal mutant *ScThrRS-G458D* nearly abolished Thr activation, with only 3.4% of remaining catalytic efficiency compared with the wild-type *ScThrRS*. Both the *K*<sub>m</sub> and *k*<sub>cat</sub> values for Thr were responsible for this drop and were obviously increased and decreased, respectively (Table 2). The severe decrease in amino acid activation was accompanied by a total loss of tRNA aminoacylation activity, which became non-measurable (Table 3). However, the *k*<sub>d</sub> for tRNA<sup>Thr</sup> was unchanged, suggesting that a loss of tRNA binding was not responsible for this inactivation (Table 4). In *EcThrRS*, Gly<sup>372</sup> ends the loop connecting the two β-strands of motif 2 (14). Adding the negatively charged side chain of Asp at this position might have modified the geometry and flexibility of the loop and following β-strand with consequent effects on the catalytic properties. Nevertheless, the structural effect probably remained local because the mutant was stable in yeast cells (Fig. 2, B and C).

*EcThrRS* uses the strictly conserved basic residue Arg<sup>375</sup> in motif 2 loop to recognize nucleotide C74 of tRNA<sup>Thr</sup> by two base-specific hydrogen bonds (14). Arg<sup>375</sup> also stabilizes the γ-phosphate of ATP during the amino acid activation step and then switches to C74 after completion of amino acid activation and pyrophosphate departure (33). A lethal mutation of Arg<sup>461</sup> (R461H) of *ScThrRS*, corresponding to Arg<sup>375</sup> from *EcThrRS*, was isolated in our selection. The amino acid activation assay showed that R461H induced a 30-fold decrease in catalytic efficiency, with a 10-fold increase of *K*<sub>m</sub> for Thr and a 3-fold decrease in *k*<sub>cat</sub> (Table 2). tRNA charging of *ScThrRS-R461H* was also undetectable; however, the *k*<sub>d</sub> value for tRNA<sup>Thr</sup> was similar to that of the wild type, which indicated that the tRNA binding site was essentially intact in the mutant (Tables 3 and 4). Western blot showed that the quantity of *ScThrRS-R461H* was close to that of wild-type *ScThrRS*, suggesting that the mutation did not affect the protein stability (Fig. 2, B and C).

The third mutation selected at position 457 (S457F) of the motif 2 loop in *ScThrRS* slightly damaged the catalytic efficiency in amino acid activation, indicated by the slightly increased *K*<sub>m</sub> for Thr (Table 2). The corresponding His<sup>371</sup> residue of *EcThrRS* is more than 4 Å from nucleotides 68–69 of tRNA<sup>Thr</sup> (Fig. 5, A and C). Here, this mutation induced a 20-fold drop of the catalytic efficiency in tRNA aminoacylation, mainly caused by a decrease of the *k*<sub>cat</sub>, whereas the *K*<sub>m</sub> and *k*<sub>d</sub> for tRNA<sup>Thr</sup> were almost unchanged (Tables 3 and 4). However, despite this severe reduction of aminoacylation activity, slight growth of the *ScΔthrS* strain could be observed (Fig. 2A), suggesting that the threshold of cell lethality was close to, but below, this value of remaining activity.

*Mutations in the C-terminal Domain*—In the crystal structure of *EcThrRS*, Gly<sup>597</sup> (the counterpart of Gly<sup>685</sup> of *ScThrRS*, selected as a lethal mutation, G685D) is located in the anticodon binding module of *EcThrRS*, in close proximity of the anticodon of tRNA<sup>Thr</sup>, which contains G35 and U36, two major identity elements of *EcThrRS* (14, 37). The distance between the carboxyl group of Gly<sup>597</sup> and G35 is only 2.96 Å (Fig. 5D). Therefore, the presence of the Asp side chain in the selected *ScThrRS-G685D* mutant might have created steric hindrance, charge repulsion, and/or loss of flexibility, potentially leading to tRNA rejection or weaker accommodation of the anticodon nucleotides. Remarkably, *ScThrRS-G685D* exhibited intact amino acid-activating properties but was unable to aminoacylate tRNA<sup>Thr</sup> (Tables 2 and 3). However, the total loss of tRNA-charging activity was not caused by a reduction of tRNA<sup>Thr</sup> affinity (Table 4). The quantity of *ScThrRS-G685D* was the same as the native *ScThrRS* in the *ScΔthrS* strain (Fig. 2C), suggesting that the protein was correctly folded and stable *in vivo*.

Deletions of the C terminus of *ScThrRS* (mutants Q704stop and Q719stop, –31 and –16 residues, respectively) failed to complement the growth of *ScΔthrS* strain and induced very low amounts compared with the wild-type enzyme (Fig. 2, A and C). These observations suggested that the last residues play a crucial role in the activity of *ScThrRS* and in protein stability. In addition, mutants *ScThrRS-Q704stop* and *-Q719stop* formed inclusion bodies in *E. coli* and could not be purified for further studies. Therefore, to study the function of the very end residues of the C terminus, we used site-directed mutagenesis to delete the 3, 5, or 10 last residues of *ScThrRS*. In the amino acid activation reaction, the three mutants, *ScThrRS-C-Δ3*, *-C-Δ5*, and *-C-Δ10*, exhibited virtually unchanged properties except for a moderate increase in the *K*<sub>m</sub> for Thr (Table 2). In the aminoacylation reaction, the three mutants displayed progressive decreases in their aminoacylation properties of 2.4–, 4.4–, and 4.9-fold, respectively, compared with wild-type *ScThrRS*. The catalytic constant *k*<sub>cat</sub> was mainly responsible for the decrease, and the *K*<sub>m</sub> for tRNA was almost unchanged (Table 3). Despite the loss of tRNA-charging activity, the three mutants were equally able to rescue the *ScΔthrS* strain as well as wild-type *ScThrRS* (Fig. 6A), suggesting that partial activity of *ScThrRS* is sufficient to sustain yeast growth. Thus, the C-terminal truncations harbor lower and lower enzymatic activities as the length of C terminus diminished; a 16-residue truncation (Q719stop), being inactive for normal physiological growth, more severely impaired the enzymatic activities.

The C-terminal domain of ThrRS binds the anticodon loop of tRNA (14). Because tRNA binding is responsible for tRNA-dependent pretransfer editing and post-transfer editing, we checked whether deletions of the C-terminal residues might affect the editing properties of *ScThrRS*. We measured AMP formation in the presence of Ser and performed mischarged tRNA deacylation assays. The three mutants showed a decrease in both tRNA-independent pretransfer editing and total editing activity, especially C-Δ5 and C-Δ10 (Table 5). However, deacylation of Ser-tRNA<sup>Thr</sup> by post-transfer editing was unaffected by the deletions (Fig. 6B), suggesting that the three mutants could still bind charged tRNA, and truncations of C-terminal amino
Selected Lethal Mutations in Threonyl-tRNA Synthetase

<figure><img src="image_6.png" /></figure>

**FIGURE 6.** Complementation phenotypes and Ser-tRNA<sup>Thr</sup> deacylation activities of C-terminal truncated ScThrRS mutants. A, drop test assay showing the complementation of the *ScΔthrS* strain by the three deleted mutants. Wild-type *ScThrRS* and empty vector p425TEF(His) were used as controls. B, deacylation activities of *ScThrRS*-WT (●) or -C-Δ3 (□), -C-Δ5 (△), or -C-Δ10 (▽). Spontaneous deacylation of Ser-tRNA<sup>Thr</sup> (○) was included as a control. *Error bar*, S.D.

acid residues had negligible influence on tRNA binding and
subsequent editing by deacylating misaminoacylated tRNA.

**Arg⁵² Library Screening Revealed Pleiotropic Effects on ScThrRS Properties**—Like many other eukaryotic aaRSs, eukaryotic ThrRSs have additional N-extensions whose functions are not yet understood. Our previous study on *ScThrRS* showed that mutants deleted of the first 40 and 65 residues (*ScThrRS*-Δ40 and *ScThrRS*-Δ65, respectively) could rescue the *thrS* knock-out strain; however, *ScThrRS*-Δ40 mutant exhibited only 25% of the wild-type charging activity, mainly because of loss of tRNA affinity (21). Examining the N-extensions of eukaryotic ThrRSs revealed the presence of several conserved or invariant residues. Arg⁵² in *ScThrRS* is one of two invariant residues (Fig. 1B). Positively charged residues are potentially able to interact with the negatively charged phosphate groups of tRNA and/or form hydrogen bond interaction with other amino acid residues (especially acid amino acid residues); therefore, we decided to study this residue using a degenerated library containing all possible amino acids at position 52. The library was constructed by site-directed mutagenesis with a randomly mutagenized primer. The Arg⁵² library was then introduced into the *ScΔthrS* strain harboring the rescuing plasmid pRS426-*ScThrRS*. 160 colonies (5 times the theoretical size library) were tested on 5-FOA-containing plates. 10 clones that could not grow on these plates contained a nonsense mutation at position 52 causing premature translation arrest. Three other clones shared a missense mutation (R52F). The gene of *ScThrRS*-R52F was cloned into p425TEF(His) vector and reintroduced into *ScΔthrS*, which confirmed its lethality for yeast (Fig. 2A).

To further analyze the lethal effect of *ScThrRS*-R52F, we
overexpressed its gene in *E. coli* and purified it. An amino acid
activation assay showed that the mutant had an unchanged *K*<sub>m</sub>
for Thr (0.23 ± 0.02 mM; wild-type, 0.22 ± 0.02 mM). However,
the catalytic rate constant (*k*<sub>cat</sub>) of the mutant was lower (1.3 ±
0.1 s<sup>-1</sup>) compared with that of the wild-type enzyme (3.2 ± 0.1
s<sup>-1</sup>), leading to a 2.6-fold drop in the catalytic efficiency (*k*<sub>cat</sub>/
*K*<sub>m</sub>) (Table 2). In contrast to amino acid activation, tRNA<sup>Thr</sup>
charging by mutant *ScThrRS*-R52F was too low to measure

<figure><img src="image_7.png" /></figure>

**FIGURE 7.** Arg⁵² mutants strongly affected ScThrRS enzymatic activities and stability. A, deacylation assay of Ser-tRNA<sup>Thr</sup> catalyzed by ScThrRS-WT (●), -R52K (■), or -R52F (□). Spontaneous hydrolysis of Ser-tRNA<sup>Thr</sup> (○) was also performed as a control. B, drop test of *ScΔthrS* strains harboring ScThrRS-R52A, -R52D, or -R52K on SD/Leu<sup>-</sup>/5-FOA plate. Cells harboring ScThrRS or empty p425TEF(His) were used as positive and negative controls, respectively. C, Western blot showing the amounts of different ScThrRS mutants in the N-extension. GAPDH was used as a loading control. D, quantification of the Western blot (WB), which has been normalized to the GAPDH control. The amount of wild-type ScThrRS was designated as 100%. Relative protein amounts were calculated based on at least two independent Western blot assays and shown in parentheses with S.D. values omitted for clarity. *Error bars*, S.D.

(Table 3). This result suggested that a deficiency of tRNA
charging was responsible for R52F lethality.

Arg⁵² is located in the N-extension that is appended to the
editing domain; therefore, we checked if the mutation affected
the editing activity. In the absence or presence of tRNA<sup>Thr</sup>, the
observed rate constants (*k*<sub>obs</sub>) of *ScThrRS*-R52F for AMP for-
mation were (0.3 ± 0.1) × 10<sup>-3</sup> s<sup>-1</sup> and (0.6 ± 0.2) × 10<sup>-3</sup> s<sup>-1</sup>,
respectively (Table 5). The latter actually reflected whole edit-
ing activities, including tRNA-independent and -dependent
pretransfer editing and post-transfer editing. These results
revealed an obvious decrease in the tRNA-dependent and
tRNA-independent editing properties. Further deacylation
assay of mischarged tRNA<sup>Thr</sup> (Ser-tRNA<sup>Thr</sup>) confirmed that
*ScThrRS*-R52F was defective in post-transfer editing (Fig. 7A).
Post-transfer editing requires proper binding of mischarged
tRNA<sup>Thr</sup> and the presence of active editing residues. Arg⁵² is
located in the N-extension, whose structure has not been
solved; therefore, it would be highly speculative to try explain-
ing the molecular effect of the mutation. Nevertheless, we can-
not exclude the possibility that the conformation of *ScThrRS-
R52F* has been altered by the mutation. Indeed, the amount of
R52F in the yeast cells was nearly undetectable by Western blot
(Fig. 2, B and C), indicating that the mutation had an effect on
protein stability or conformation or both, together with signif-
icant effects on aminoacylation and editing activities.

For a better understanding of the effect of R52F, and despite
the fact that the Arg⁵² library theoretically covered all possible
mutations, we performed additional site-directed mutagenesis
at the Arg⁵² position. We substituted Arg⁵² for Ala (smaller side
chain), Asp (negatively charged), and Lys (positively charged).
# Selected Lethal Mutations in Threonyl-tRNA Synthetase

<table><caption>**TABLE 6**
Catalytic kinetic parameters of ScThrRS-WT and -R52A in the tRNA aminoacylation reaction</caption><thead><tr><th>Kinetic parameters<sup>a</sup></th><th>WT</th><th>R52A</th></tr></thead><tbody><tr><td><strong>Transcript CGU</strong></td><td></td><td></td></tr><tr><td>k<sub>cat</sub> (×10<sup>-2</sup> s<sup>-1</sup>)</td><td>3.4 ± 0.2</td><td>0.2 ± 0.03</td></tr><tr><td>K<sub>m</sub> (µM)</td><td>1.3 ± 0.2</td><td>1.2 ± 0.2</td></tr><tr><td>Relative k<sub>cat</sub>/K<sub>m</sub> (%)</td><td>100</td><td>5.7</td></tr><tr><td><strong>Transcript UGU</strong></td><td></td><td></td></tr><tr><td>k<sub>cat</sub> (×10<sup>-2</sup> s<sup>-1</sup>)</td><td>4.5 ± 0.5</td><td>0.3 ± 0.1</td></tr><tr><td>K<sub>m</sub> (µM)</td><td>1.4 ± 0.2</td><td>1.3 ± 0.1</td></tr><tr><td>Relative k<sub>cat</sub>/K<sub>m</sub> (%)</td><td>100</td><td>6.7</td></tr></tbody></table>

In the amino acid activation reaction, ScThrRS-R52K, -R52A, and -R52D displayed $K_m$ values similar to that of the wild-type ScThrRS and catalytic efficiencies of 106.4, 51.7, and 42.0%, respectively (Table 2). Surprisingly, tRNA-charging assays showed that mutant ScThrRS-R52D was totally unable to aminoacylate tRNA<sup>Thr</sup>. Mutants ScThrRS-R52A and -R52K displayed unchanged $K_m$ values, but the $k_{cat}$ of ScThrRS-R52A for tRNA charging was dramatically decreased, leading to a global loss of catalytic efficiency of nearly 25.7-fold (Table 3). The catalytic efficiency of ScThrRS-R52K decreased by 1.8-fold compared with that of wild-type (Table 3). Further hydrolysis of mischarged Ser-tRNA<sup>Thr</sup> showed that R52K moderately decreased the post-transfer editing activity (Fig. 7A). These biochemical data confirmed that Arg<sup>52</sup> is important for the aminoacylation and editing activities, although the residue was replaced by the same charge Lys. When the three ScThrRS-R52D, -R52A, and -R52K mutants were tested for complementation of the ScΔthrS strain, it appeared that ScThrRS-R52D was lethal to yeast, whereas ScThrRS-R52A and -R52K could rescue ScΔthrS similarly to the wild-type ScThrRS (Fig. 7B). Western blot analysis of yeast extracts showed that the amount of ScThrRS-R52K was equal to the wild-type ScThrRS (Fig. 7, C and D). In contrast, the amounts of ScThrRS-R52A and -R52D were significantly decreased, to 2.7 and 4.6%, respectively (Fig. 7, C and D). This observation supported the hypothesis that Arg<sup>52</sup> is critical for protein stability. It is also remarkable that ScThrRS-R52A was able to rescue the *thrS* knock-out strain with only 1/37 of the amount of wild-type protein and a 23.1-fold loss of aminoacylation activity. However, this extremely low activity of ScThrRS-R52A was measured with the transcript of tRNA<sup>Thr</sup>(AGU), and yeast contains three different tRNA<sup>Thr</sup> isoacceptors to decode the four Thr codons; therefore, ScThrRS-R52A might be more active for one or both of the two other isoacceptors.

With this suspicion in mind, we decided to further analyze the kinetic parameters of ScThrRS-R52A for other isoacceptors during aminoacylation. We therefore used *in vitro* transcription to synthesize the two other isoacceptors (CGU and UGU) and determined their charging capacities. The catalytic efficiencies of ScThrRS-R52A for CGU and UGU reached 5.7 and 6.7%, respectively, compared with the wild-type enzyme (Table 6). These values were about 1.5-fold higher, but not much better, than that of transcript AGU (relative $k_{cat}/K_m$ = 4.3%) and confirmed that only a very small fraction of tRNA<sup>Thr</sup>-accepting activity is sufficient to support protein synthesis *in vivo*.

Several aaRSs, such as LysRS (38) and MetRS (39), have N-extensions that are rich in basic residues and can bind nonspecifically tRNA elements. To determine if the ThrRS N-extension was similarly involved in tRNA binding, we measured the $k_d$ values of the two lethal mutants identified at position 52. The analysis showed that both ScThrRS-R52F and ScThrRS-R52D had full tRNA binding capacity (Table 4), indicating that this residue does not contribute significantly to tRNA binding. Altogether, the effects induced by R52A, R52D, and R52F strongly suggest that this part of the N-extension of ThrRS plays a critical role in catalysis, structure, and/or the stability of this enzyme.

*The Yeast thrS Knock-out Strain as a Useful Tool to Analyze Mutations in Human Cytoplasmic ThrRS*—Human cytoplasmic ThrRS comprises 723 amino acid residues and shows 53.8% sequence identity to ScThrRS. Here, 12 mutations were found in the two mutated ScThrRS libraries, and eight of the mutated residues were conserved in HsThrRS and ScThrRS (Fig. 1, A and C). This high homology between the two proteins allows HsThrRS to complement the yeast knock-out strain deprived of ScThrRS, ScΔthrS (21). We could use this complementation to test point mutations experimentally introduced into HsThrRS. An increasing number of point mutations causing various types of human diseases have been identified in aaRSs (40); therefore, the availability of a cellular system designed to test new mutations would be helpful.

To verify that the complementation assay of the *thrS* knock-out strain assay can be used with confidence to analyze mutated HsThrRS, we introduced the eight conserved missense mutations and one truncation in ScThrRS into HsThrRS. The eight mutations were single substitutions (R57F, S301F, G349N, G451D, R454H, G595E, P618L, and G677D) (Fig. 1, A and C), and the truncation was a deletion of the 11 residues of the C terminus (L711stop). Genes corresponding to these mutants were cloned into p425TEF(His) and introduced into ScΔthrS strain. All transformants grew well on SD/Leu<sup>-</sup>/Ura<sup>-</sup> plates, but none could grow in the SD/Leu<sup>-</sup> medium containing 5-FOA (Fig. 8A). The synthesis of the mutated proteins was confirmed by Western blot (Fig. 8B). Overall, the gene expression patterns of the HsThrRS mutants were very similar to those of the ScThrRS mutants (Figs. 2C and 8C). Some mutants, such as HsThrRS-G451D, -R454H, -G595E, and -G677D, were found in the same amounts as native HsThrRS, despite being lethal. However, mutants HsThrRS-R57F, -S301F, -G349N, -P618L, and -L711stop were present at about 5% of the relative amounts of either ScThrRS or HsThrRS, suggesting that these amino acid residues play similar functional and structural roles in both ThrRSs (Figs. 2C and 8C).

Considering that G145D, S457F, and C-Δ3 of ScThrRS were not lethal, we further confirmed whether the ScΔthrS strain could be used to test the function of HsThrRS mutations by introducing A149D, T450F, and C-Δ3 (corresponding to G145D, S457F, and C-Δ3 of ScThrRS, respectively) into HsThrRS. We found that yeast containing HsThrRS-C-Δ3 was growth-deficient and the other two mutations were lethal (data not shown). ScThrRS-C-Δ3 was viable (Fig. 6A), despite exhibiting a 2.4-fold loss of aminoacylation activity (Table 2), but cognate HsThrRS-C-Δ3 led to a significant deficiency in the

<footnote><sup>a</sup> Results are shown as the average of three independent trials ± S.D.</footnote>
Selected Lethal Mutations in Threonyl-tRNA Synthetase

<figure><img src="image_8.png" /><figcaption>FIGURE 8. Complementation of the yeast *thrS* knock-out strain by *HsThrRS* mutants. A, complementation of *ScΔthrS* strain by *HsThrRS* mutants corresponding to the *ScThrRS* lethal mutants. p425TEF(His) constructs hARBoring wild-type *HsThrRS*, -R57F, -S301F, -G349N, -G451D, -R454H, -G595E, -P618L, -G677D, and -L711stop were transformed into *ScΔthrS*. Equal amounts of cells of each transformant were dropped onto a SD/Leu-/5-FOA plate. Wild-type *ScThrRS* and empty p425TEF(His) were used as positive and negative controls, respectively. B, Western blot showing the amounts of *HsThrRS* mutants. GAPDH was used as a control. C, quantification of the Western blot, normalized to the GAPDH control. The amount of *HsThrRS* was designated as 100%. Relative protein amounts were calculated based on at least two independent Western blot assays and shown parentheses with S.D. values omitted for clarity.</figcaption></figure>

growth of the *ScΔthrS* strain. These observations suggested that aminoacylation activities of *HsThrRS* mutants *in vivo* could be analyzed sensitively by the yeast *thrS* knock-out strain.

Overall, these initial results highlighted the strong correlation between sequence homology of the human and yeast cytoplasmic ThrRSs, and some critical functional and structural properties were observed in both enzymes. These data will be useful for future analyses of the potential pathological mechanism of identified mutations of *HsThrRS* in the future.

DISCUSSION

*A Genetic Screen to Identify Functional Elements in ThrRS*—
ThrRS is a remarkable aaRS because it exhibits a specific modular structure in the class II synthetase family. It has also

evolved a novel strategy of amino acid recognition and a proof-
reading activity (14). This prompted us to perform a genetic
selection to isolate random mutations inducing the loss of
ThrRS functions. To detect the loss of function, we used a
genetic selection in *S. cerevisiae* based on the *thrS* gene knock-
out strain. By plasmid shuffling, we isolated 12 mutations (11
and 1, respectively, from randomly and site-directed mutagen-
esis libraries) inducing lethal or growth-deficient phenotypes.
The mutations are spread over the four main functional
domains of *ScThrRS*. In addition, after carefully checking pre-
vious biochemical studies on ThrRS, we found that only Arg³⁷⁵
of *EcThrRS* (corresponding to our selected Arg⁴⁶¹ of *ScThrRS*)
has been studied by structural analyses (33). Arg⁴⁶¹ of *ScThrRS*
mutation was lethal in our study, which is consistent with the
structural research. We provided the first evidence to show the
functional significance of the other 11 residues of *ScThrRS*,
including Arg⁵², Gly¹⁴⁵, Ser³⁰⁸, Gly³⁵⁶, Ser⁴⁵⁷, Gly⁴⁵⁸, Gly⁶⁰⁴,
Pro⁶²⁷, Gly⁶⁸⁵, Gln⁷⁰⁴, and Gln⁷¹⁹.

Mutations in the Editing Site Simultaneously Affected the tRNA Proofreading and Aminoacylation—In the editing domain, mutations G145D and S308F induced a severe defect of editing activities. The crystal structure of *EcThrRS* shows that the two residues do not directly interact with the tRNA acceptor arm and CCA sequence into the editing site (14). Thus, an indirect effect would probably be responsible for the decrease of editing activity. Gly⁶⁷ (Gly¹⁴⁵ in *ScThrRS*) is located in helix H3 containing the signature sequence ⁷³HXXXH⁷⁷, which is involved in the hydrolytic process of mischarged tRNA (41). Therefore, the G145D mutation might have modified the flexibility and conformation of the catalytic helix H3, which might explain its loss of post-transfer editing. Similarly, Ala²²² in *EcThrRS*, corresponding to Ser³⁰⁸ in yeast, is located before the α-helix bridging the editing and aminoacylation domains (14). The insertion of a bulky Phe residue in the S308F mutant might have modified the relative orientations of the two domains, with pleiotropic effects on synthetic, editing activities and mutant stability. Furthermore, G145D and S308F strongly decreased tRNA aminoacylation, despite being more than 30 Å from the synthetic site (14). The decrease of tRNA charging observed in the two mutants might also result from an inefficient editing activity. Actually, a full cycle of aminoacylation comprises the tRNA-charging step and, after translocation of the CCA acceptor end, the proofreading step in the editing site. Alteration of one step will definitely affect the rate of the next cycle, which might explain the parallel effect on tRNA charging and post-transfer editing.

*Mutations in the Synthetic Active Site*—Three mutations were isolated in the loop of class II-defining motif 2 and one in motif 3. According to the structural data, three of these mutations (S457F, G458D, and G604E) do not alter direct contacts with the substrates (14). However, the location of the residues and nature of the substitutions indicated that the damaging effects could have resulted from local structural changes resulting from steric hindrance with other side chains. It resulted in a loss of the synthetic activities, despite good protein stability. A fourth mutant, R461H, is remarkable in that it modifies an Arg residue that directly binds ATP during amino acid activation and then, after pyrophosphate departure, interacts with nucle-
Selected Lethal Mutations in Threonyl-tRNA Synthetase

otide C74 of tRNA during the transfer step (33). A conservative mutation was isolated during the screening procedure (R461H), confirming that this residue is critical and could not tolerate any change.

**Lethal Mutations Also Target Dimerization of ThrRS**—Class II aaRSs share three conserved motifs, one of which is involved in dimer formation (4, 42). Indeed, dimerization is essential for efficient formation of the active sites of AspRS (43), LysRS (44), and ProRS (45). However, dimerization is not strictly required for class II aaRS activity, and natural monomeric PheRSs exist in mitochondria (46). Similarly, a truncated monomeric *E. coli* AlaRS could complement *in vivo* in cells (47). ThrRS is a dimer with a typical class II interface between the two aminoacylation sites (14). Here, the analyses of G356N and P627L showed that dimerization is also a critical prerequisite for ScThrRS activity, as already observed with other class II synthetases. For the closely related LysRS, the dimeric character of LysRS was essential to stabilize the subunits in a productive conformation (44). The properties of the lethal mutants studied here fully support this view.

**Binding of the Anticodon Controls tRNA Aminoacylation Activity**—The C-terminal residues of aaRSs are sometimes essential for the enzymatic activity (48, 49). In *E. coli* tRNA<sup>Thr</sup>, all of the bases from 32 to 37 interact through at least one hydrogen bond to the protein, and bases 35–38 are splayed out from the anticodon loop (14), indicating that the tRNA recognition cleft is a mobile region. This is consistent with the observation that almost identical *K*<sub>m</sub> values were determined for *E. coli* tRNA<sup>Thr</sup> isoacceptors having C, G, or U at position 34 (37), despite only C34 directly binding to the enzyme and interacting with N575 (14). It is also interesting to note that a hydrogen bond was found between N2 of G35 and O4 of U36 (14). In addition, a highly conserved acidic residue Glu<sup>600</sup> of *EcThrRS* lying adjacent to Gly<sup>597</sup> (analogous to Gly<sup>685</sup> of *ScThrRS*) makes a direct hydrogen bond with N1 of G35 (14). In brief, the conformational flexibility of the tRNA binding site, the novel base interaction between G35 and U36, and the mutation of Gly<sup>685</sup> into acidic Asp might explain why the selected G685D lethal mutation did not affect the initial binding of tRNA to the synthetase, as shown by the *k*<sub>d</sub> measurement.

**An N-terminal Appended Domain with Critical Residues**— One distinct feature in the structural evolution of aaRSs is the appending of sequences at the amino or C terminus. These new domains are generally thought to be dispensable for aminoacylation but are responsible for a number of new noncanonical functions, such as multisynthetase complex formation, transcription regulation, translation control, and neurodegeneration (50). For example, in the multisynthetase complex, the C-terminal extension of LeuRS is dispensable for enzymatic activity but critical for the interaction with the N-terminal of ArgRS (32). Eukaryotic ThrRS has evolved an N-extension harboring several highly conserved residues, such as Arg<sup>52</sup>. We found that R52F and R52D mutations are lethal, inhibiting aminoacylation and reducing protein stability *in vivo*. Appended domains were reported to enhance tRNA binding through non-specific tRNA binding interactions (51–53), and no critical residue has been described in these extensions. The Arg<sup>52</sup> mutant of *ScThrRS* and the equivalent mutant in *HsThrRS* are the first

examples of lethal mutants described in the N-extension that reduced both aminoacylation and editing properties. This shows that the appended domains can play key roles in regulating the enzymatic activities of the catalytic core.

Interestingly, *ScThrRS-R52A* could support the growth of the *ScΔthrS* strain with a 23-fold loss of aminoacylation activity plus 33-fold lower protein amount, as compared with the native enzyme. However, *ScThrRS-G145D* and *S457F*, which caused less severe aminoacylation and expression defects, led to growth deficiency. Mutation of the residue Ser<sup>457</sup> of the motif 2 loop into Phe probably impedes aminoacylation directly, because the motif 2 loop is crucial for the correct positioning of the tRNA acceptor end and amino acid binding (33). *ScThrRS-G145D* exhibited a severe decrease in post-transfer editing; its low enzymatic activity probably resulted from the impaired aminoacylation cycle of tRNA charging and proofreading. In contrast to the direct impact on tRNA charging and editing caused by S457F and G145D mutations, it seems that R52A indirectly weakened the catalytic efficiency through impairing protein stability or conformation/structure. The indirect influence of R52A mutation might be diminished *in vivo* in unidentified manners, such as assistance of chaperones, product release, or interaction with other translation factors. As a consequence, *ScThrRS-R52A* is more efficient in producing Thr-tRNA<sup>Thr</sup> and is viable enough to complement the *ScΔthrS* strain.

**Analyzing and Characterizing Human aaRS/tRNA Pathogenetic Mutations**—Since the first example of human genetic disease-related mutation in an aaRS was reported in 2003, when GlyRS was implicated in Charcot-Marie-Tooth disease (10), an increasing number of aaRSs has been revealed to cause human diseases (40). We show that the high sequence conservation between *HsThrRS* and *ScThrRS* is suitable to perform complementation assays of the yeast ThrRS knock-out strain by *HsThrRS* or mutated derivatives. Loss of function mutations selected in yeast ThrRS and transplanted in human cytoplasmic ThrRS induce very similar defects, indicating that the yeast strain can be used to gain insights into the pathological mechanisms induced by human ThrRS mutations in the future, although no mutations have currently been linked pathologically with the human cytoplasmic ThrRS gene. Recently, a spontaneous mutation of human mitochondrial ThrRS P282L was reported to cause mitochondrial encephalopathies (54). The ThrRS knock-out system designed to test cellular function might also be helpful to examine the effects of this P282L mutation and establish an *in vivo* functional diagnosis.

Six different mutations in human mitochondrial tRNA<sup>Thr</sup> (see the Compilation of Mammalian Mitochondrial tDNA Genes Web site, Université de Strasbourg) have been identified to induce human diseases, including mitochondrial myopathies, lethal infantile mitochondrial myopathy, Alzheimer and Parkinson disease, and Leber hereditary optic neuropathy. Yeast was reported as a platform to understand the cellular role of human pathogenetic mitochondrial tRNAs, because mitochondrial tRNA sequence and function between yeast and humans are general conservative (55). For example, the A14G substitution of yeast mitochondrial tRNA<sup>Leu</sup>(UUR) caused equivalent aminoacylation defects and structure alterations to
the A3243G human pathogenetic tRNA mutation (56). A similar yeast tRNA<sup>Thr</sup> knock-out system may be easily constructed and adapted to investigate *in vivo* the impact of tRNA<sup>Thr</sup> mutations and also provide insights into the cellular mechanism of tRNA-associated mitochondrial diseases.

REFERENCES

1. Ibba, M., and Soll, D. (2000) Aminoacyl-tRNA synthesis. *Annu. Rev. Biochem.* **69**, 617–650

2. Rould, M. A., Perona, J. J., Söll, D., and Steitz, T. A. (1989) Structure of *E. coli* glutaminyl-tRNA synthetase complexed with tRNA<sup>Gln</sup> and ATP at 2.8 Å resolution. *Science* **246**, 1135–1142

3. Cusack, S., Berthet-Colominas, C., Härtlein, M., Nassar, N., and Leberman, R. (1990) A second class of synthetase structure revealed by x-ray analysis of *Escherichia coli* seryl-tRNA synthetase at 2.5 Å. *Nature* **347**, 249–255

4. Eriani, G., Delarue, M., Poch, O., Gangloff, J., and Moras, D. (1990) Partition of tRNA synthetases into two classes based on mutually exclusive sets of sequence motifs. *Nature* **347**, 203–206

5. Chen, J. F., Guo, N. N., Li, T., Wang, E. D., and Wang, Y. L. (2000) CP1 domain in *Escherichia coli* leucyl-tRNA synthetase is crucial for its editing function. *Biochemistry* **39**, 6726–6731

6. Ling, J., Reynolds, N., and Ibba, M. (2009) Aminoacyl-tRNA synthesis and translational quality control. *Annu. Rev. Microbiol.* **63**, 61–78

7. Zhou, X., and Wang, E. (2013) Transfer RNA: a dancer between charging and mis-charging for protein biosynthesis. *Sci. China Life Sci.* **56**, 921–932

8. Zhou, X. L., Du, D. H., Tan, M., Lei, H. Y., Ruan, L. L., Eriani, G., and Wang, E. D. (2011) Role of tRNA amino acid-accepting end in aminoacylation and its quality control. *Nucleic Acids Res.* **39**, 8857–8868

9. Reynolds, N. M., Ling, J., Roy, H., Banerjee, R., Repasky, S. E., Hamel, P., and Ibba, M. (2010) Cell-specific differences in the requirements for translation quality control. *Proc. Natl. Acad. Sci.* **107**, 4063–4068

10. Antonellis, A., Ellsworth, R. E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S. Q., Jordanova, A., Kremensky, I., Christodoulou, K., Middleton, L. T., Sivakumar, K., Ionasescu, V., Funalot, B., Vance, J. M., Goldfarb, L. G., Fischbeck, K. H., and Green, E. D. (2003) Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. *Am. J. Hum. Genet.* **72**, 1293–1299

11. Banks, G. T., Bros-Facer, V., Williams, H. P., Chia, R., Achilli, F., Bryson, J. B., Greensmith, L., and Fisher, E. M. (2009) Mutant glycyl-tRNA synthetase (Gars) ameliorates SOD1(G93A) motor neuron degeneration phenotype but has little affect on Loa dynein heavy chain mutant mice. *PloS One* **4**, e6218

12. Jordanova, A., Irobi, J., Thomas, F. P., Van Dijck, P., Meerschaert, K., Dewil, M., Dierick, I., Jacobs, A., De Vriendt, E., Guergueltcheva, V., Rao, C. V., Tournev, I., Gondim, F. A., D'Hooghe, M., Van Gerwen, V., Callaerts, P., Van Den Bosch, L., Timmermans, J. P., Robberecht, W., Gettemans, J., Thevelein, J. M., De Jonghe, P., Kremensky, I., and Timmerman, V. (2006) Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. *Nat. Genet.* **38**, 197–202

13. Lee, J. W., Beebe, K., Nangle, L. A., Jang, J., Longo-Guess, C. M., Cook, S. A., Davisson, M. T., Sundberg, J. P., Schimmel, P., and Ackerman, S. L. (2006) Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. *Nature* **443**, 50–55

14. Sankaranarayanan, R., Dock-Bregeon, A. C., Romby, P., Caillet, J., Springer, M., Rees, B., Ehresmann, C., Ehresmann, B., and Moras, D. (1999) The structure of threonyl-tRNA synthetase-tRNA<sup>Thr</sup> complex enlightens its repressor activity and reveals an essential zinc ion in the active site. *Cell* **97**, 371–381

15. Ribas de Pouplana, L., and Schimmel, P. (2001) Aminoacyl-tRNA synthetases: potential markers of genetic code development. *Trends Biochem. Sci.* **26**, 591–596

16. Sankaranarayanan, R., Dock-Bregeon, A. C., Rees, B., Bovee, M., Caillet, J., Romby, P., Francklyn, C. S., and Moras, D. (2000) Zinc ion mediated amino acid discrimination by threonyl-tRNA synthetase. *Nat. Struct. Biol.* **7**, 461–465

17. Dock-Bregeon, A., Sankaranarayanan, R., Romby, P., Caillet, J., Springer, M., Rees, B., Francklyn, C. S., Ehresmann, C., and Moras, D. (2000) Transfer RNA-mediated editing in threonyl-tRNA synthetase: the class II solution to the double discrimination problem. *Cell* **103**, 877–884

18. Beebe, K., Merriman, E., Ribas De Pouplana, L., and Schimmel, P. (2004) A domain for editing by an archaebacterial tRNA synthetase. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 5958–5963

19. Korencic, D., Ahel, I., Schelert, J., Sacher, M., Ruan, B., Stathopoulos, C., Blum, P., Ibba, M., and Söll, D. (2004) A freestanding proofreading domain is required for protein synthesis quality control in Archaea. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 10260–10265

20. Shimizu, S., Juan, E. C., Sato, Y., Miyashita, Y., Hoque, M. M., Suzuki, K., Sagara, T., Tsunoda, M., Sekiguchi, T., Dock-Bregeon, A. C., Moras, D., and Takénaka, A. (2009) Two complementary enzymes for threonylation of tRNA in crenarchaeota: crystal structure of *Aeropyrum pernix* threonyl-tRNA synthetase lacking a cis-editing domain. *J. Mol. Biol.* **394**, 286–296

21. Zhou, X. L., Ruan, Z. R., Huang, Q., Tan, M., and Wang, E. D. (2013) Translational fidelity maintenance preventing Ser mis-incorporation at Thr codon in protein from eukaryote. *Nucleic Acids Res.* **41**, 302–314

22. Springer, M., Graffe, M., Dondon, J., and Grunberg-Manago, M. (1989) tRNA-like structures and gene regulation at the translational level: a case of molecular mimicry in *Escherichia coli*. *EMBO J.* **8**, 2417–2424

23. Caillet, J., Nogueira T., Masquida B., Winter F., Graffe M., Dock-Brégeon A. C., Torres-Larios A., Sankaranarayanan R., Westhof E., Ehresmann B., Ehresmann C., Romby P., and Springer M. (2003) The modular structure of *Escherichia coli* threonyl-tRNA synthetase as both an enzyme and a regulator of gene expression. *Mol. Microbiol.* **47**, 961–974

24. Ador L., Camasses A., Erbs P., Cavarelli J., Moras D., Gangloff J., and Eriani G. (1999) Active site mapping of yeast aspartyl-tRNA synthetase by *in vivo* selection of enzyme mutations lethal for cell growth. *J. Mol. Biol.* **288**, 231–242

25. Mumberg, D., Müller, R., and Funk, M. (1995) Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. *Gene* **156**, 119–122

26. Rasila, T. S., Pajunen, M. I., and Savilahti, H. (2009) Critical evaluation of random mutagenesis by error-prone polymerase chain reaction protocols, *Escherichia coli* mutator strain, and hydroxylamine treatment. *Anal. Biochem.* **388**, 71–80

27. Wong, T. S., Roccatano, D., Zacharias, M., and Schwaneberg, U. (2006) A statistical analysis of random mutagenesis methods used for directed protein evolution. *J. Mol. Biol.* **355**, 858–871

28. Jazwinski, S. M. (1990) Preparation of extracts from yeast. *Methods Enzymol.* **182**, 154–174

29. Gruic-Sovulj, I., Uter, N., Bullock, T., and Perona, J. J. (2005) tRNA-dependent aminoacyl-adenylyl hydrolysis by a nonediting class I aminoacyl-tRNA synthetase. *J. Biol. Chem.* **280**, 23978–23986

30. Tan, M., Zhu, B., Zhou, X. L., He, R., Chen, X., Eriani, G., and Wang, E. D. (2010) tRNA-dependent pre-transfer editing by prokaryotic leucyl-tRNA synthetase. *J. Biol. Chem.* **285**, 3235–3244

31. Yarus, M., and Berg, P. (1970) On the properties and utility of a membrane filter assay in the study of isoleucyl-tRNA synthetase. *Anal. Biochem.* **35**, 450–465

32. Ling, C., Yao, Y. N., Zheng, Y. G., Wei, H., Wang, L., Wu, X. F., and Wang, E. D. (2005) The C-terminal appended domain of human cytosolic leucyl-tRNA synthetase is indispensable in its interaction with arginyl-tRNA synthetase in the multi-tRNA synthetase complex. *J. Biol. Chem.* **280**, 34755–34763

33. Torres-Larios, A., Sankaranarayanan, R., Rees, B., Dock-Bregeon, A. C., and Moras, D. (2003) Conformational movements and cooperativity upon amino acid, ATP and tRNA binding in threonyl-tRNA synthetase. *J. Mol. Biol.* **331**, 201–211

34. Cavarelli, J., Eriani, G., Rees, B., Ruff, M., Boeglin, M., Mitschler, A., Martin, F., Gangloff, J., Thierry, J. C., and Moras, D. (1994) The active site of yeast aspartyl-tRNA synthetase: structural and functional aspects of the aminoacylation reaction. *EMBO J.* **13**, 327–337

35. Arnez, J. G., Augustine, J. G., Moras, D., and Francklyn, C. S. (1997) The first step of aminoacylation at the atomic level in histidyl-tRNA synthe-
Selected Lethal Mutations in Threonyl-tRNA Synthetase

tase. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 7144–7149

36. Eriani, G., Cavarelli, J., Martin, F., Ador, L., Rees, B., Thierry, J. C., Gangloff, J., and Moras, D. (1995) The class II aminoacyl-tRNA synthetases and their active site: evolutionary conservation of an ATP binding site. *J. Mol. Evol.* **40**, 499–508

37. Hasegawa, T., Miyano, M., Himeno, H., Sano, Y., Kimura, K., and Shimizu, M. (1992) Identity determinants of *E. coli* threonine tRNA. *Biochem. Biophys. Res. Commun.* **184**, 478–484

38. Francin, M., Kaminska, M., Kerjan, P., and Mirande, M. (2002) The N-terminal domain of mammalian lysyl-tRNA synthetase is a functional tRNA-binding domain. *J. Biol. Chem.* **277**, 1762–1769

39. Kaminska, M., Shalak, V., and Mirande, M. (2001) The appended C-domain of human methionyl-tRNA synthetase has a tRNA-sequestering function. *Biochemistry* **40**, 14309–14316

40. Antonellis, A., and Green, E. D. (2008) The role of aminoacyl-tRNA synthetases in genetic diseases. *Annu. Rev. Genomics Hum. Genet.* **9**, 87–107

41. Dock-Bregeon, A. C., Rees, B., Torres-Larios, A., Bey, G., Caillet, J., and Moras, D. (2004) Achieving error-free translation; the mechanism of proofreading of threonyl-tRNA synthetase at atomic resolution. *Mol. Cell* **16**, 375–386

42. Arnez, J. G., and Moras, D. (1997) Structural and functional considerations of the aminoacylation reaction. *Trends Biochem. Sci.* **22**, 211–216

43. Eriani, G., Cavarelli, J., Martin, F., Dirheimer, G., Moras, D., and Gangloff, J. (1993) Role of dimerization in yeast aspartyl-tRNA synthetase and importance of the class II invariant proline. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 10816–10820

44. Commans, S., Blanquet, S., and Plateau, P. (1995) A single substitution in the motif 1 of *Escherichia coli* lysyl-tRNA synthetase induces cooperativity toward amino acid binding. *Biochemistry* **34**, 8180–8189

45. Lee, M. L., and Muench, K. H. (1969) Prolyl transfer ribonucleic acid synthetase of *Escherichia coli*. *J. Biol. Chem.* **244**, 223–230

46. Sanni, A., Walter, P., Boulanger, Y., Ebel, J. P., and Fasiolo, F. (1991) Evolution of aminoacyl-tRNA synthetase quaternary structure and activity: *Saccharomyces cerevisiae* mitochondrial phenylalanyl-tRNA synthetase. *Proc. Natl. Acad. Sci. U.S.A.* **88**, 8387–8391

47. Jasin, M., Regan, L., and Schimmel, P. (1983) Modular arrangement of functional domains along the sequence of an aminoacyl tRNA synthetase. *Nature* **306**, 441–447

48. Hsu, J. L., Rho, S. B., Vannella, K. M., and Martinis, S. A. (2006) Functional divergence of a unique C-terminal domain of leucyl-tRNA synthetase to accommodate its splicing and aminoacylation roles. *J. Biol. Chem.* **281**, 23075–23082

49. Hu, Q. H., Huang, Q., and Wang, E. D. (2013) Crucial role of the C-terminal domain of *Mycobacterium tuberculosis* leucyl-tRNA synthetase in aminoacylation and editing. *Nucleic Acids Res.* **41**, 1859–1872

50. Guo, M., Yang, X. L., and Schimmel, P. (2010) New functions of aminoacyl-tRNA synthetases beyond translation. *Nat. Rev. Mol. Cell Biol.* **11**, 668–674

51. Frugier, M., Moulinier, L., and Giegé, R. (2000) A domain in the N-terminal extension of class IIb eukaryotic aminoacyl-tRNA synthetases is important for tRNA binding. *EMBO J.* **19**, 2371–2380

52. Cahuzac, B., Berthonneau, E., Birlirakis, N., Guittet, E., and Mirande, M. (2000) A recurrent RNA-binding domain is appended to eukaryotic aminoacyl-tRNA synthetases. *EMBO J.* **19**, 445–452

53. Wang, C. C., and Schimmel, P. (1999) Species barrier to RNA recognition overcome with nonspecific RNA binding domains. *J. Biol. Chem.* **274**, 16508–16512

54. Diodato, D., Melchionda, L., Haack, T. B., Dallabona, C., Baruffini, E., Donnini, C., Granata, T., Ragona, F., Balestri, P., Margollicci, M., Laman tea, E., Nasca, A., Powell, C. A., Minczuk, M., Strom, T. M., Meitinger, T., Prokisch, H., Lamperti, C., Zeviani, M., and Ghezzi, D. (2014) VARS2 and TARS2 mutations in patients with mitochondrial encephalomyopathies. *Hum. Mutat.* **35**, 983–989

55. Rinaldi, T., Dallabona, C., Ferrero, I., Frontali, L., and Bolotin-Fukuhara, M. (2010) Mitochondrial diseases and the role of the yeast models. *FEMS Yeast Res.* **10**, 1006–1022

56. Montanari, A., Besagni, C., De Luca, C., Morea, V., Oliva, R., Tramontano, A., Bolotin-Fukuhara, M., Frontali, L., and Francisci, S. (2008) Yeast as a model of human mitochondrial tRNA base substitutions: investigation of the molecular basis of respiratory defects. *RNA* **14**, 275–283
<figure><img src="image_9.png" /></figure>

**Enzymology:**

**Identification of Lethal Mutations in Yeast
Threonyl-tRNA Synthetase Revealing
Critical Residues in Its Human Homolog**

Zhi-Rong Ruan, Zhi-Peng Fang, Qing Ye,
Hui-Yan Lei, Gilbert Eriani, Xiao-Long Zhou
and En-Duo Wang

J. Biol. Chem. 2015, 290:1664-1678.

doi: 10.1074/jbc.M114.599886 originally published online November 21, 2014

ENZYMOLOGY

<figure><img src="image_10.png" /></figure>

Access the most updated version of this article at doi: 10.1074/jbc.M114.599886

Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites.

**Alerts:**

* When this article is cited

* When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 56 references, 21 of which can be accessed free at
http://www.jbc.org/content/290/3/1664.full.html#ref-list-1